Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells

Ye, Shuting; Hou, Zhengjun; Su, Yayun; Ye, Miya; Liu, Tairan; Ying, Weiwei; Su, Meiyun

doi:10.1007/s13204-021-02010-3

Cited by 4 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The poly(lactic-co-glycolic acid) NPs (PLGA-NPs) encapsulating the anticancer drug Losmapimod (LOS) have been examined to explore the impact of multiple myeloma (MM) cancer cells. 125 The human MM cancer cell line used for anticancer activity is U266 and IM9. The in-vitro studies have shown that LOS@PLGA-NPs trigger cell death in cancer cells, further preventing the migration and invasion of MM cancer cell lines.…”

Section: Application In Cancer Treatmentmentioning

confidence: 99%

RETRACTED: An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment

Dristant

Mukherjee

Saha

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Cancer is recognized as one of the world's deadliest diseases, with more than 10 million new cases each year. Over the past 2 decades, several studies have been performed on cancer to pursue solutions for effective treatment. One of the vital benefits of utilizing nanoparticles (NPs) in cancer treatment is their high adaptability for modification and amalgamation of different physicochemical properties to boost their anti-cancer activity. Various nanomaterials have been designed as nanocarriers attributing nontoxic and biocompatible drug delivery systems with improved bioactivity. The present review article briefly explained various types of nanocarriers, such as organic–inorganic-hybrid NPs, and their targeting mechanisms. Here a special focus is given to the synthesis, benefits, and applications of polymeric NPs (PNPs) involved in various anti-cancer therapeutics. It has also been discussed about the drug delivery approach by the functionalized/encapsulated PNPs (without/with targeting ability) that are being applied in the therapy and diagnostic (theranostics). Overall, this review can give a glimpse into every aspect of PNPs, from their synthesis to drug delivery application for cancer cells.

show abstract

Section: Application In Cancer Treatmentmentioning

confidence: 99%

RETRACTED: An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment

Dristant

Mukherjee

Saha

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Losmapimod (LOS), a solid and selective p38 MAPK inhibitor, was developed to treat disorders characterized by cytokine-dependent proinflammatory processes, such as COPD. In the first clinical trial, Losmapimod 7.5 mg reduced plasma fibrinogen by 11% and improved hyperinflation in mild COPD patients [16][17][18]. It has been shown that the drugs reduce fibrinogen levels in a subgroup of participants with blood eosinophils by 2%.…”

Section: Introductionmentioning

confidence: 99%

Fabrication of gemcitabine and losmapimod-prodrug loaded nanoparticles for the treatment and care of lung cancer

Zhao

Qi²

2022

Mater. Res. Express

View full text Add to dashboard Cite

Lung carcinoma (LC) is rare cancer in most parts of the world but is common cancer in southern Asia. Local recurrent disease and distant metastasis of LC are still mysterious challenges. This investigation was to effectively fabricate and evaluate the therapeutic efficiency of Gemcitabine (GEM) and Losmapimod (LOS) encapsulated into polyethylene glycol (PEG)-polylactic-co-glycolic acid (PLGA)-NPs (GEM/LOS@NPs), which exhibited inhibition of in vitro lung cells proliferation. GEM/LOS@NPs with a diameter of ~100 nm have been constructed employing an enhanced double-emulsion (W/O/W) method. The GEM/LOS@NPs' particle size was studied through transmission electron microscopic (TEM) techniques and dynamic light scattering (DLS) measurement. After successfully fabricating GEM/LOS@NPs, the anticancer ability of A549 and H460 lung cancer cells was investigated. Biochemical assays such as AO/EB (acridine bromide/orange ethidium) and nuclear staining investigated the cancer cell's morphology and death. The cell death of the cancer cells was synergically examined by ROS analysis. Overall, these results suggest that highly toxic drugs can be rationally transformed into self-deliverable and pharmacologically efficient monotherapy.

show abstract

Recent advances in targeted drug delivery systems for multiple myeloma

Pant,

Laliwala,

Holstein

et al. 2024

Journal of Controlled Release

View full text Add to dashboard Cite

Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells

Cited by 4 publications

References 57 publications

RETRACTED: An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment

RETRACTED: An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment

Fabrication of gemcitabine and losmapimod-prodrug loaded nanoparticles for the treatment and care of lung cancer

Recent advances in targeted drug delivery systems for multiple myeloma

Contact Info

Product

Resources

About